S&P Futures
6,004.25 +0.50 (+0.01%) Dow Futures
43,897.00 -13.00 (-0.03%) Nasdaq Futures
21,230.00 +5.25 (+0.02%) Russell 2000 Futures
2,395.70 0.00 (0.00%) Crude Oil
71.77 -0.59 (-0.82%) Gold
2,695.70 -10.10 (-0.37%)
Eyenovia, Inc. (EYEN)
After hours:
| Previous Close | 0.5002 |
| Open | 0.5100 |
| Bid | 0.4679 x 400 |
| Ask | 0.5065 x 600 |
| Day's Range | 0.4817 - 0.5175 |
| 52 Week Range | 0.3700 - 2.5700 |
| Volume | |
| Avg. Volume | 1,588,733 |
| Market Cap | 41.655M |
| Beta (5Y Monthly) | 1.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7800 |
| Earnings Date | Nov 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.83 |
GlobeNewswireEyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th
Company to host an investor conference call and webcast at 4:30pm EDTNEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that the Company will release financial results for the third quarter ended September 30, 2024 on Tuesday, November 12th, 2024, after the markets close. Following the relea
- GlobeNewswire
Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®
Publication in the Journal of Ocular Pharmacology and Therapeutics highlights the ability of the Optejet to achieve a therapeutic dose of medication with far less exposure to harmful preservatives Additional presentation at the American Academy of Optometry summarizes a Phase 4 study of Mydcombi demonstrating that clinically relevant mydriasis can be achieved with a half-dose per eye NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, toda
